JAK2 and myeloproliferative neoplasm: These findings collectively suggest that resveratrol is a JAK2 inhibitor with considerable clinical relevance, given that dysregulated JAK2 activity is involved in the pathogenesis of hematological diseases such as myeloproliferative neoplasms [56].